These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 28223378)

  • 21. Pharmacokinetic/Pharmacodynamic Analysis for Doripenem Regimens in Intensive Care Unit Patient.
    Tanaka R; Sato Y; Goto K; Yasuda N; Ohchi Y; Suzuki Y; Ueno T; Ito K; Kaneko T; Kurogi S; Nonoshita K; Itoh H
    Biol Pharm Bull; 2017; 40(8):1226-1231. PubMed ID: 28769004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
    Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH
    Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
    Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients.
    Matsuo Y; Ishibashi T; Shimamura K; Wajima T
    J Pharm Sci; 2015 Sep; 104(9):3194-8. PubMed ID: 25821174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.
    Bhavnani SM; Hammel JP; Cirincione BB; Wikler MA; Ambrose PG
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3944-7. PubMed ID: 16127078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
    Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
    Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients.
    Ikawa K; Nomura K; Morikawa N; Ikeda K; Ohge H; Sueda T; Taniwaki M
    J Infect Chemother; 2008 Apr; 14(2):130-6. PubMed ID: 18622676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.
    Cirillo I; Vaccaro N; Castaneda-Ruiz B; Redman R; Cossey V; Bradley JS; Allegaert K
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4742-9. PubMed ID: 26014957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.
    Fournier A; Goutelle S; Que YA; Eggimann P; Pantet O; Sadeghipour F; Voirol P; Csajka C
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E).
    Namiki T; Yokoyama Y; Hashi H; Oda R; Jibiki A; Kawazoe H; Matsumoto K; Suzuki S; Nakamura T
    Pharmacotherapy; 2024 Feb; 44(2):149-162. PubMed ID: 37984818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function.
    Kim SW; Choe S; Kim DJ; Zang DY; Lee DH
    Ther Drug Monit; 2018 Aug; 40(4):425-434. PubMed ID: 29746394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
    J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.